Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma

Introduction: Atezolizumab and bevacizumab (Ate/Bev) combination has become the new first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). Although several studies reported thyroid dysfunction after treatment with immune checkpoint inhibitors, the clinical and immunological sig...

Full description

Bibliographic Details

Published in:	Liver Cancer
Main Authors:	Young Shin Song, Hannah Yang, Beodeul Kang, Jaekyung Cheon, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Ho Yeong Lim, Vincent E. Gaillard, Chan Kim, Hong Jae Chon
Format:	Article
Language:	English
Published:	Karger Publishers 2023-05-01
Subjects:	hepatocellular carcinoma thyroid adverse events atezolizumab bevacizumab
Online Access:	https://beta.karger.com/Article/FullText/531182